Table 1 Variables acquired from the SMART-AV clinical trial

General Characteristics (10)

Sex, Age, Height, Weight, Systolic Blood Pressure (BPsys), Diastolic Blood Pressure (BPdia), Heart Rate at Rest (HRrest), QOL Score, 6-Minute Walk Distance, Center size

Comorbidities (10)

Atrial Fibrillation (Afib), Paroxysmal Atrial Fibrillation (PAF), Atrial Flutter, Renal Disease, Chronic Obstructive Pulmonary Disease (COPD), Premature Ventricular Contractions (PVC), Atrial Tachycardia Paroxysmal Supraventricular Tachycardia (AT-PSVT), History of Left Bundle Branch Block (LBBB), History of Right Bundle Branch Block (RBBB), Ischemic Cardiomyopathy

Surgical History (3)

Sinoatrial (SA) Node Surgery, Coronary Artery Bypass Graft (CABG), Pre-Cutaneous Coronary Intervention (PCI)

Medications (3)

Diuretics, Ace inhibitors or ARBs (ACE-ARB), Digoxin

Echo-based Assessment (6)

Left Ventricular End Diastolic Volume (LVEDV), Left Ventricular End Systolic Volume (LVESV), Left Ventricular Ejection Fraction (LVEF), Stroke Volume (SV), EDV/ESV, 1-Dimensional Stretch (cube root of EDV/ESV)

ECG (12)

AV Interval without Atrial Pacing, PR Interval without Atrial Pacing, QRS Width, VT None, VT Nonsustained, VT Supraventricular Tachycardia (VT-SVT), Sick Sinus, Paced AV Delay, Echo Optimized AV Delay, Iterative AV Delay, Fixed AV Delay, Sensed AV Delay

Circulating Biomarkers (12)

Matrix Metalloproteinase 2 (MMP-2), Matrix Metalloproteinase 9 (MMP9), Soluble Suppression of Tumorigenicity 2 (sST-2), C-Reactive Protein (CRP), N-terminal pro B-type Natriuretic Peptide (NT- proBNP), Tissue Inhibitors of Metalloproteinase 1 (TIMP1), Tissue Inhibitors of Metalloproteinase 2 (TIMP2), Tissue Inhibitors of Metalloproteinase 4 (TIMP4), Soluble Glycoprotein 130 (sGP130), Soluble Interleukin 2 Receptor Alpha (sIL2Ra), Tumor Necrosis Factor Receptor II (sTNFR-II), Interferon Gamma (IFNg)